What's Happening?
Hormone therapy (HT) for menopausal women, including those with rheumatic diseases, is undergoing reconsideration following new research that challenges previous concerns about cardiovascular and cancer risks. Dr. Stephanie Faubion, Director at the Mayo
Clinic Center for Women’s Health, highlighted that women younger than 60 or less than 10 years post-menopause are prime candidates for HT, especially if they experience bothersome vasomotor, mood, and sleep problems, have bone density concerns, and no excess risk of breast cancer or cardiovascular disease. The timing of HT initiation is crucial; estrogen may offer the most benefit during perimenopause and early postmenopause, as older women with pre-existing vascular disease may face increased risks of heart attack and stroke with estrogen, particularly oral forms. Nonhormonal therapies like Fezolinetant and Elinzanetant are also available for vasomotor symptoms and sleep disturbances.
Why It's Important?
This re-evaluation of HT is significant for millions of U.S. women, particularly those navigating menopause and co-occurring conditions like rheumatic diseases. The initial concerns raised by a 2002 study led to a drastic reduction in HT use, potentially leaving many women to suffer from severe menopausal symptoms without effective treatment. The updated understanding, emphasizing individualized risk assessment and timing, allows for more nuanced and potentially beneficial treatment plans. For women with systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARDs), HT can offer relief from vasomotor symptoms, vaginal dryness, and increased bone density, provided they are negative for antiphospholipid syndrome and have stable disease. This shift can improve the quality of life for a substantial portion of the female population and refine clinical practice guidelines.
What's Next?
The discussion at ACR Convergence 2026 emphasized shared decision-making between patients and healthcare providers regarding HT. The 2020 ACR Guideline conditionally recommends HT for patients with SARDs experiencing severe vasomotor symptoms. Low-dose transdermal HT is presumed to have lower thrombotic risk for severe symptoms, and vaginal estrogen may help with local symptoms with minimal systemic absorption. Further research is needed, especially on transdermal HT in antiphospholipid antibody patients or SARDs. The availability of newer nonhormonal options like Fezolinetant and Elinzanetant provides additional tools for managing menopausal symptoms, offering alternatives for women who are not candidates for HT or prefer non-hormonal approaches. Continued education for rheumatologists and other specialists is crucial to implement these updated guidelines effectively.
Beyond the Headlines
The evolving understanding of HT reflects the dynamic nature of medical science and the importance of continuous research to refine treatment paradigms. The initial broad-stroke concerns about HT, followed by a more granular understanding of risks and benefits based on individual patient factors and timing, highlight the complexities of medical decision-making. This situation also underscores the impact of scientific findings on public perception and medical practice, demonstrating how initial interpretations can lead to widespread changes that are later adjusted with more comprehensive data. For women's health advocacy, it reinforces the need for ongoing research and personalized medicine approaches to ensure that treatments are tailored to individual needs and risk profiles, moving away from one-size-fits-all solutions.
